Precision BioSciences, Inc. (DTIL) stock analysis
Healthcare · Biotechnology
From the 10-K filed 2026-03-12
Business type: Asset play
How it makes money
It earns by securing upfront and milestone payments from biopharmaceutical partners for the licensing and collaborative development of its proprietary gene editing therapies.
The business operates as a research-intensive entity rather than a commercial product seller. Because it has not yet commercialized any therapies, its primary inflow of funds consists of cash received from strategic partners who sponsor the advancement of its ARCUS platform and specific internal programs.
What protects it: the moat
It relies on its proprietary ARCUS genome editing platform and a broad intellectual property portfolio to differentiate itself from competitors.
Management asserts that the unique structural properties of its ARCUS nucleases—specifically their small size, single-component nature, and specific cut patterns—create a competitive advantage over established CRISPR or other nuclease technologies. It actively works to expand and defend the legal protections surrounding these technological innovations.
What growth costs
It must heavily reinvest in research, development, and clinical trials to maintain its technology and pursue future commercialization.
The company incurs significant expenses to conduct preclinical and clinical studies, expand laboratory facilities, and sustain the administrative costs of operating as a public company. Because it lacks commercial products, there are no meaningful costs associated with manufacturing at scale or distribution at this time.
What could damage it
A failure to achieve clinical success in its trials would stop the flow of partner milestone payments and exhaust its ability to raise capital.
The company’s survival depends on its ability to validate its platform in humans. If clinical results for its lead programs, such as PBGENE-HBV, do not meet expectations, it cannot generate revenue from its current research, nor can it secure the equity or debt funding required to sustain its high burn rate, leading to a permanent impairment of operations.
About Precision BioSciences, Inc.
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits, as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; and PBGENE-DMD (Excision) for the treatment of Duchenne muscular dystrophy. In addition, the company develops PBGENE-3243 for the treatment of m.3243 associated mitochondrial diseases; and iECURE-OTC (Insertion) for ornithine transcarbamylase deficiency. It has collaboration agreements with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azercabtagene zapreleucel for autoimmune diseases and other indications; and iECURE, Inc., an ARCUS-mediated targeted gene insertion. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.